Marco A Lorio1, Rossana Rosa2, Jose F Suarez1, Phillip Ruiz3, Gaetano Ciancio3, George W Burke3, Jose F Camargo2. 1. Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 2. Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA. 3. Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA.
Abstract
BACKGROUND: HIV infection is associated with high rates of acute rejection following kidney transplantation. The underlying mechanisms for such predisposition are incompletely understood. Pathological immune activation is a hallmark of chronic HIV infection that persists despite effective antiretroviral therapy. We hypothesized that the baseline levels of T cell activation in HIV(+) candidates would correlate with their risk of acute rejection following kidney transplantation. METHODS: Single-center retrospective cohort analysis of HIV(+) adult kidney transplants performed between October 2006 and September 2013. The frequency of CD3(+)HLA-DR(+) cells measured by flow cytometry served as a surrogate marker of immune activation. Patients were categorized into tertiles of activation, and the rates of biopsy-proven acute rejection were compared across groups. RESULTS: (1) Compared to matched HIV(-) controls, the baseline number of CD3(+)HLA-DR(+) cells was higher in HIV(+) kidney transplant candidates. (2) Abnormally high levels of activation did not decrease with transplant-associated immunosuppression. (3) Patients categorized within the lower and middle CD3(+)HLA-DR(+) tertiles had higher probability of rejection during the first 3years post-transplant compared to those in the higher activation tertile (36.9% vs. 0%; log-rank P=0.04). CONCLUSIONS: Pathological immune activation in HIV(+) transplant candidates does not explain their increased susceptibility to allograft rejection. Paradoxically, those with the highest levels of immune activation seem to be less prone to rejection.
BACKGROUND:HIV infection is associated with high rates of acute rejection following kidney transplantation. The underlying mechanisms for such predisposition are incompletely understood. Pathological immune activation is a hallmark of chronic HIV infection that persists despite effective antiretroviral therapy. We hypothesized that the baseline levels of T cell activation in HIV(+) candidates would correlate with their risk of acute rejection following kidney transplantation. METHODS: Single-center retrospective cohort analysis of HIV(+) adult kidney transplants performed between October 2006 and September 2013. The frequency of CD3(+)HLA-DR(+) cells measured by flow cytometry served as a surrogate marker of immune activation. Patients were categorized into tertiles of activation, and the rates of biopsy-proven acute rejection were compared across groups. RESULTS: (1) Compared to matched HIV(-) controls, the baseline number of CD3(+)HLA-DR(+) cells was higher in HIV(+) kidney transplant candidates. (2) Abnormally high levels of activation did not decrease with transplant-associated immunosuppression. (3) Patients categorized within the lower and middle CD3(+)HLA-DR(+) tertiles had higher probability of rejection during the first 3years post-transplant compared to those in the higher activation tertile (36.9% vs. 0%; log-rank P=0.04). CONCLUSIONS: Pathological immune activation in HIV(+) transplant candidates does not explain their increased susceptibility to allograft rejection. Paradoxically, those with the highest levels of immune activation seem to be less prone to rejection.
Authors: Jayme E Locke; Nathan T James; Roslyn B Mannon; Shikha G Mehta; Peter G Pappas; John W Baddley; Niraj M Desai; Robert A Montgomery; Dorry L Segev Journal: Transplantation Date: 2014-02-27 Impact factor: 4.939
Authors: Mysore S Anil Kumar; Debra R Sierka; Anna M Damask; Billie Fyfe; Robert F McAlack; Michael Heifets; Michael J Moritz; Daniel Alvarez; Aparna Kumar Journal: Kidney Int Date: 2005-04 Impact factor: 10.612
Authors: Jayme E Locke; Shikha Mehta; Rhiannon D Reed; Paul MacLennan; Allan Massie; Anoma Nellore; Christine Durand; Dorry L Segev Journal: J Am Soc Nephrol Date: 2015-03-19 Impact factor: 10.121
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Jose F Camargo; Hemant Kulkarni; Brian K Agan; Alvaro A Gaitan; Lisa A Beachy; Sowmya Srinivas; Weijing He; Stephanie Anderson; Vincent C Marconi; Matthew J Dolan; Sunil K Ahuja Journal: J Infect Dis Date: 2009-06-15 Impact factor: 5.226
Authors: Christine M Durand; Wanying Zhang; Diane M Brown; Sile Yu; Niraj Desai; Andrew D Redd; Serena M Bagnasco; Fizza F Naqvi; Shanti Seaman; Brianna L Doby; Darin Ostrander; Mary Grace Bowring; Yolanda Eby; Reinaldo E Fernandez; Rachel Friedman-Moraco; Nicole Turgeon; Peter Stock; Peter Chin-Hong; Shikha Mehta; Valentina Stosor; Catherine B Small; Gaurav Gupta; Sapna A Mehta; Cameron R Wolfe; Jennifer Husson; Alexander Gilbert; Matthew Cooper; Oluwafisayo Adebiyi; Avinash Agarwal; Elmi Muller; Thomas C Quinn; Jonah Odim; Shirish Huprikar; Sander Florman; Allan B Massie; Aaron A R Tobian; Dorry L Segev Journal: Am J Transplant Date: 2020-08-08 Impact factor: 9.369
Authors: Rossana Rosa; Jose F Suarez; Marco A Lorio; Michele I Morris; Lilian M Abbo; Jacques Simkins; Giselle Guerra; David Roth; Warren L Kupin; Adela Mattiazzi; Gaetano Ciancio; Linda J Chen; George W Burke; Jose M Figueiro; Phillip Ruiz; Jose F Camargo Journal: F1000Res Date: 2016-12-21
Authors: Jose F Camargo; Suresh Pallikkuth; Ilona Moroz; Yoichiro Natori; Maria L Alcaide; Allan Rodriguez; Giselle Guerra; George W Burke; Savita Pahwa Journal: Kidney Int Rep Date: 2019-08-19